HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

• Conditions: Solid Tumor
• Interventions: Drug: HuMax-IL8

• Registration Number: NCT02536469
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.

Detailed Description

All human subjects with a diagnosis of incurable solid tumors are eligible for the dose-escalation phase of this study. This study consists of two phases, the dose-escalation phase and the expansion phase. Subjects will be treated with the study treatment until any off-treatment criteria are met. The safety and efficacy will be assessed until the end of treatment or for a maximum of 52 weeks. In addition, a separate visit will be performed at the time of disease progression if the patient has a progression between end of treatment and 52 weeks. The patients will be followed up for overall survival until the study closure. The study will be closed when all enrolled patients have been followed up for at least 52 weeks or have died.

Study Timeline

• Study Start: 2015-08
• Study First Submitted: 2015-08-23
• Study First Submitted QC: 2015-08-28
• Study First Posted: 2015-08-31
• Primary Completion: 2016-11
• Study Completion: 2016-11
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-01
• Last Update Posted: 2017-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Subjects must have metastatic or unresectable locally advanced malignant solid tumor.
• Patients may have measurable or non-measurable but evaluable disease.
• Patients with surgically resected metastatic disease at high risk of relapse are also eligible.
• Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be candidates for therapy of proven efficacy for their disease.
• Patients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapy
• Age ≥ 18 years. .
• ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1 (Karnofsky ≥ 70%).
• Patients must have normal organ and hematologic function therapy
• Patients must have baseline pulse oximetry > 90% on room air

Read More

Exclusion Criteria

• Pregnant women or women presently breast-feeding
• Concurrent treatment for cancer
• Chronic hepatitis B or C infection.
• Any significant disease that, in the opinion of the investigator, may impair the patient's tolerance of study treatment.
• Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
• Active autoimmune diseases requiring treatment or a history of autoimmune disease.
• Concurrent use of systemic steroids
• Patients who are receiving any other investigational agents
• Patients with untreated central nervous system metastases or local treatment of brain metastases
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study.
• Serious or uncontrolled intercurrent illness
• HIV-positive patients are ineligible
• Patients unwilling to use adequate contraception

Other protocol defined inclusion/exclusion criteria could apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
HuMax-IL8	HuMax-IL8	HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle

Primary Outcome Measures

Name	Time	Method
Proportion of patients who experience DLTs (Dose Limiting Toxicity) 28 days following the first dose of HuMax-IL8, as well as all DLTs occurring during the study thereafter.	From cycle 1 day 1 up to 28 days	The primary endpoint of this study is the proportion of patients who experience DLTs. The MTD (Maximum Tolerated Dose) will be determined based on the dose escalation cohorts. The evaluation period for DLTs will be 28 days following the first dose of HuMax-IL8

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic properties of HuMax-IL8 in patients including AUC (Area Under the Curve)	From baseline up to 72 hours after infusion

Trial Locations

Locations (1)

National Cancer Institute; 🇺🇸 Bethesda, Maryland, United States